Arthropathies due to Microcrystals — Expert Clinical Reference

Internal Medicine · Clinical Specialties

How it begins

Referencia exhaustiva de nivel experto sobre gota, artropatía por pirofosfato de calcio (CPPD), depósito de fosfato básico de calcio (BCP) y artropatía por oxalato. Fisiopatología molecular, diagnóstico, criterios de clasificación y tratamiento actualizado (EULAR 2016 / ACR 2020).

What it covers

1. Arthropathies due to Microcrystals
2. 1. Introduction and Classification of Microcrystal Arthropathies
3. 2. Shared Molecular Pathophysiology
4. · 2.1 The NLRP3 Inflammasome — Central Axis of Crystal Inflammation
5. · 2.2 Differences in Inflammatory Potency by Crystal Type
6. 3. Analysis of Synovial Fluid in Microcrystal Arthropathies
7. · 3.1 Polarized Light Microscopy — Interpretation
8. 4. Gout: Epidemiology, Risk Factors and Hyperuricemia
9. · 4.1 Uric Acid Metabolism
10. · 4.2 Hyperuricemia: Definition and Mechanisms
11. · 4.3 Risk Factors for Gout
12. 5. Pathophysiology of MSU Deposition and Tophi Formation
13. · 5.1 MSU Nucleation and Precipitation
14. · 5.2 Formation of Gouty Tophus
15. 6. Clinical Spectrum of Gout
16. · 6.1 Asymptomatic Hyperuricemia
17. · 6.2 Acute Gouty Arthritis
18. · 6.3 Intercritical Drop
19. · 6.4 Chronic Tophaceous Gout
20. 7. Diagnosis and Classification Criteria of Gout
21. · 7.1 ACR/EULAR 2015 Classification Criteria
22. · 7.2 Laboratory in Gota
23. 8. Image in the Drop
24. · 8.1 Simple X-ray
25. · 8.2 Musculoskeletal Ultrasound — Characteristic Findings
26. · 8.3 Dual Energy CT (DECT) — Non-Invasive Gold Standard
27. 9. Treatment of Acute Gout Attack
28. · 9.1 NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
29. · 9.2 Colchicine
30. · 9.3 Corticosteroids
31. · 9.4 IL-1 Inhibitors (Anti-IL-1)
32. 10. Long-Term Hypoglycemic Therapy
33. · 10.1 When to Start Hypourice-lowering Treatment?
34. · 10.2 Xanthine Oxidase Inhibitors (XOI)
35. · 10.3 Uricosurics
36. · 10.4 Recombinant Uricases — Refractory Drop
37. 11. Gout in Special Situations
38. · 11.1 Gout and Chronic Kidney Disease
39. · 11.2 Gout in Organ Transplantation
40. · 11.3 Gout and Cardiovascular Disease
41. 12. Calcium Pyrophosphate Arthropathy (CPPD) — General
42. · 12.1 Pathophysiology of CPP Deposition
43. · 12.2 Metabolic Conditions Associated with CPPD
44. 13. CPPD Clinical Forms
45. · 13.1 Asymptomatic PDPH (Incidental Radiological Chondrocalcinosis)
46. · 13.2 Acute Arthritis due to CPP (Pseudogout)
47. · 13.3 Chronic Arthropathy due to CPP (Rheumatoid Pseudoarthritis and Rapidly Destructive OA)
48. 14. Diagnosis of CPPD
49. · 14.1 Simple X-ray — Chondrocalcinosis
50. · 14.2 Ultrasound in CPPD
51. 15. Treatment of arthropathy due to CPPD
52. · 15.1 Treatment of Acute Attack of Pseudogout
53. · 15.2 Prophylaxis and Chronic Treatment
54. 16. Basic Calcium Phosphate (BCP) Deposition / Calcifying Tendinitis and Milwaukee Syndrome
55. · 16.1 Calcifying tendinitis (HADD)
56. · 16.2 Milwaukee syndrome
57. 17. Calcium Oxalate Arthropathy
58. · 17.1 Primary Oxalosis (Types I, II and III)
59. · 17.2 Secondary Oxalosis (Terminal Renal Failure and Dialysis)
60. 18. Global Comparative Table of Microcrystal Arthropathies
61. 19. Advanced Imaging in Microcrystal Arthropathies
62. · 19.1 Magnetic Resonance
63. · 19.2 DECT in Microcrystal Arthropathies
64. · 19.3 PET-CT in Gota
65. 20. Fundamental Clinical Correlations
66. · 20.1 Integrated Diagnostic Algorithm in Acute Monoarticular Arthritis